Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole: case reports

R S PATTMAN,⁎ M S SPROTT,† A M KEARNS,† M EARNSHAW‡

From the *Department of Genitourinary Medicine; the †Regional Public Health Laboratory; and the ‡Department of Pharmacy, Newcastle General Hospital, Newcastle upon Tyne

SUMMARY  After a recent report showing the in vitro susceptibility to mebendazole of a strain of Trichomonas vaginalis that was resistant to metronidazole, we present two cases of metronidazole resistant infection, both of which failed to respond to oral mebendazole.

Since 1960 the oral 5-nitroimidazole, metronidazole, which gives cure rates of 86–100%, has been available as the treatment of choice for vaginal trichomoniasis in non-gravid women.¹ Other nitroimidazoles have been shown to be equally effective.² Since 1978, however, the emergence of strains of Trichomonas vaginalis that are resistant to metronidazole has been reported.³⁷ This resistance appears to be associated with greatly decreased susceptibility to the other available 5-nitroimidazoles, tinidazole and nimo- razole.⁸ Alternative treatment is obviously necessary.

In January 1988 Sears and O'Hare reported on the in vitro activity of 50 different antimicrobial agents against five strains of T vaginalis.⁹ Four were susceptible to metronidazole, but the fifth was resistant. Against this metronidazole resistant strain three agents, anisomycin, furazolidone, and mebendazole were reported as being active. Only the latter is available in this country. As two women attending this department of genitourinary medicine were infected with T vaginalis that was established as being resistant to metronidazole, we decided, with their informed consent, to assess the efficacy of mebendazole.

Case reports

CASE 1

A single woman (a nurse) aged 22 attended in December 1987 with trichomonal vaginitis. She had apparently acquired her infection in September 1987 while in Israel, and had already been given metronidazole but had not experienced symptomatic improvement. She was treated initially with a combination of metronidazole (400 mg twice a day for seven days) and ampicillin (250 mg four times a day for five days), both by mouth. The ampicillin was prescribed to cover the possibility of associated metronidazole inactivating organisms. Subsequent endocervical cultures gave negative results for Neisseria gonorrhoeae but positive for Chlamydia trachomatis. Triple tetracycline was therefore prescribed in a dose of 300 mg twice a day for two weeks. As the trichomoniasis persisted, she was given concurrent nirmorazole 1 g every 12 hours for three days.

On further review she remained heavily infected with T vaginalis. She had not had sexual intercourse. Her serum zinc concentration was 10·1 μmol/l (normal range 9·5–17 μmol/l). The minimum inhibitory concentration (MIC) of metronidazole against the organism under aerobic conditions was 125 μg/ml (control strain 1 μg/ml), and the MIC of nimorazole was 4 μg/ml (control strain 2 μg/ml). Oral mebendazole was prescribed in a dosage of 100 mg twice a day for three days, and the patient was also asked to insert two 100 mg mebendazole tablets into her vagina at night. She returned after a week with continuing trichomoniasis, and stated that the mebendazole had failed to dissolve in her vagina. She was then given oral mebendazole only, 400 mg three times a day for one week, to be taken with fatty food. Again she failed to respond clinically or microbiologically, but tolerated the treatment apart from slight gastrointestinal hurry.

CASE 2

A married housewife aged 50 was referred by her general practitioner in January 1988 with a four year history of recurrent trichomoniasis, which had failed to respond to numerous courses of metronidazole. She had refrained from sexual intercourse during this time and claimed that her husband had already received epidemiological treatment with metronidazole. Hysterectomy had been performed two years previously for menorrhagia.

Trichomonal vaginitis was confirmed microscopi-
Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole: case reports

cally, and she was treated initially with a combination of oral metronidazole (400 mg twice a day for seven days) and ampicillin (250 mg four times a day for five days). Endocervical cultures for *N gonorrhoeae* and *C trachomatis* repeatedly gave negative results, and her serum zinc concentration was 11.3 μmol/l (normal range 9.5–17 μmol/l). The MIC of metronidazole against the *T vaginalis* strain isolated on culture was 32 mg/l under aerobic conditions.

At review her condition was unchanged, and she was given oral nimorazole (1 g every 12 hours for 36 hours) in combination with povidone-iodine pessaries (200 mg inserted at night for seven days). No improvement was seen clinically or microbiologically so we prescribed oral mebendazole, initially in a dose of 400 mg twice a day for seven days and then 400 mg three times a day for seven days, advising the patient to take the tablets with fatty foods. At follow up, her symptoms were unaltered, and numerous trichomonads were found in the vaginal fluid. She reported no side effects.

**Discussion**

Mebendazole resistant strains of *T vaginalis* were identified in both patients after they had received repeated previous treatment with this agent. Forsgren and Forssman have suggested that suboptimal doses of mebendazole in vaginal secretions may induce imidazole resistance. Low plasma zinc concentrations have been reported as being related to recalcitrant vaginal trichomoniasis, and a therapeutic response to metronidazole occurred only when plasma zinc concentrations returned to normal after a three week course of oral zinc sulphate. In both our patients serum zinc concentrations were within the normal range. Treatment failure related to the presence of organisms that inactivate metronidazole has been reported by several authors. In this view of this, our current policy for patients with recalcitrant trichomoniasis is to submit samples of vaginal secretions for bacteriological culture and to prescribe a combination of metronidazole and ampicillin. Additional vaginal swabs taken from one patient (case 1) showed two types of diphtheroids and a metronidazole resistant penicillin sensitive streptococcus that failed to grow, even on prolonged culture, in other than anaerobic atmospheres. The other patient (case 2) yielded diphtheroids, *Streptococcus faecalis*, coagulase negative staphylococci, and metronidazole resistant penicillin sensitive *Bacteroides melaninogenicus*. Although the potentially inactivating organisms showed sensitivity to ampicillin, the patients failed to respond to routine combination treatment with ampicillin and metronidazole.

Alternative treatment with 5-nitroimidazoles proved to be unsuccessful. These agents are apparently absorbed passively by *T vaginalis*. Their nitro group is thought to be reduced by hydrogenosomes in the cytoplasm under anaerobic conditions to form cytotoxic nitro radical anions.

Sears and O’Hare observed that a metronidazole resistant laboratory strain of *T vaginalis* (aerobic MIC 100 mg/l) was much more susceptible in vitro to mebendazole (aerobic MIC 3·1 mg/l). Mebendazole is a microtubular inhibitor indicated for treating patients with helminthic infections. Münst, Karlagamis, and Bircher have shown that when 1·5 g mebendazole was administered to three fasting patients their plasma concentrations did not exceed 17 nmol/l, but when mebendazole was given with food peak plasma concentrations reached 91 to 142 nmol/l within two to four hours. They advised giving mebendazole with food, as we recommended to our patients. Our limited experience showed that using the oral mebendazole tablet as a vaginal pessary was unsuccessful because it failed to dissolve. Although one patient experienced slight gastrointestinal hurry, there were no serious side effects. Unfortunately, however, neither of our patients experienced any therapeutic effect.

**References**

Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole: case reports.
R S Pattman, M S Sprott, A M Kearns and M Earnshaw

doi: 10.1136/sti.65.4.274

Updated information and services can be found at: http://sti.bmj.com/content/65/4/274

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/